Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. - Test2 - elhamkhani - TriplyDB

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

http://www.wikidata.org/entity/Q33894467

about

Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children Oral versus intra-vaginal imidazole and triazole anti-fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children Fungicidal activity of fluconazole against Candida albicans in a synthetic vagina-simulative medium Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents Antifungal resistance in pathogenic fungi A Clinician's Guide to the Diagnosis and Treatment of Candidiasis in Patients with Psoriasis Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants Population pharmacokinetics of fluconazole in young infants.Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobia Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces.Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins.Candida pseudorugosa sp. nov., a novel yeast species from sputum.Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of Amer Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.A screening assay based on host-pathogen interaction models identifies a set of novel antifungal benzimidazole derivatives.Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species Antifungal susceptibility testing of fluconazole by flow cytometry correlates with clinical outcome.Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent.Micafungin.Influence of liposomal amphotericin B on CD8 T-cell function.Iron acquisition from transferrin by Candida albicans depends on the reductive pathway.Urinary D-arabinitol/L-arabinitol levels in infants undergoing long-term antibiotic therapy Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods.Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection Fluconazole dose recommendation in urinary tract infection.Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.Prophylactic antifungal therapy in the intensive care unit.Treatment of intra-abdominal abscesses caused by Candida albicans with antifungal agents and recombinant murine granulocyte colony-stimulating factor Nosocomial candiduria: a review.Vertebral osteomyelitis due to Candida species: case report and literature review.Fungal infections in older adults.

P2860

Q24234875-40856DCB-A6B3-4C5C-AFEC-2FEF9EDDF021 Q24236693-0CD58A40-109E-4353-9DD7-F3A699AD6A7C Q24243315-94D6C5A2-C0F0-4CEF-BC1F-61B35ABC08E9 Q24244997-8D59F311-3445-4194-B456-F428507EC01E Q24630977-F08ABB88-1E3C-41F3-83C6-ADB809F654BC Q26863344-3134823D-FEAA-48D2-A8DF-7C20BF682262 Q28208165-B573FD44-3E5C-47F0-80DA-D95732927E8D Q30248908-517B7F6B-2305-4D63-AE5B-946A603B9568 Q30433993-9846B390-2D68-4898-A19C-8C260D3F8050 Q30435365-815C5CDC-5CA2-48F8-94CF-AE440770A576 Q30439710-8B7F7CBD-0497-4704-B096-74F2B7D332AC Q30452376-2E85310E-822F-4B3D-A0DC-CCDFCF21CFDB Q30452973-71FA90DF-3F60-4CFD-8B9F-CEACE864D414 Q30452976-17056FC7-0490-4BF6-991A-985ECFE9F144 Q30453797-8A93F320-877E-4B62-8C5C-F178A1D26AC4 Q30799502-7166F473-C27A-4A8F-A893-A073D7BF9369 Q31058690-BE3F49F6-C579-4D6D-9EF3-CCC195C1B760 Q31064491-40383877-C2BA-45B7-9178-DDCEADD8CC48 Q33183542-98B5DED0-CC6A-4703-9BDF-1B32F4FF1A1D Q33650105-0082D148-7327-4286-8F3C-C6A7B522FA7A Q33938082-585AB790-50BD-4D63-B29E-B93960CF6E13 Q33957538-24A351D9-32CF-49B4-94E7-0D9A3D3570DE Q33964454-BE6A552D-AC93-4D0F-8F69-E2319E3E62E6 Q33972828-30B512A2-1F83-494D-B7D3-76A9AA8BD0DF Q33980499-3483CBCF-3770-4638-B20C-D96EBB3819D8 Q33981019-1B55BB46-D6E5-4EDF-82C3-B45DAFC07C93 Q33982820-2E287B4D-E92A-4B69-BE86-2680660E2D31 Q34033963-826FE212-7F17-44AA-97E0-1240B2A1E164 Q34073552-7DC5AA00-4DA2-4F20-A433-5C2672B1D89A Q34105475-C9B7BBD0-3B92-4FEF-9FD6-880828F7EA28 Q34109559-A99B6C33-6870-4C64-8795-583A43169C18 Q34142406-B9405D6D-D2C7-4AD4-BDF7-BB19EBC4A1A4 Q34142971-63ABFF2E-64C3-49D2-ABDB-85229562578D Q34191338-7852674F-F139-4340-870C-859282EB4178 Q34202154-876DAF2C-88A2-4E0F-904A-0B36AD864698 Q34205622-56629726-EAB7-402D-9D22-6C95DA5B1605 Q34230759-4F24B5BA-C0D7-4EB1-ABC4-A71E98F99EA2 Q34243460-8D42DD56-1EB1-4938-9E00-5AE4706EA374 Q34312887-9D287C70-AE93-451E-AB81-3C6DD246C174 Q34312894-28BDCC03-6C23-4659-9779-C64CD8C52C8A

P2860

Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America.

http://www.wikidata.org/entity/Q33894467

description

2000 nî lūn-bûn

@nan

2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Practice guidelines for the tr ...... s Diseases Society of America.

@ast

Practice guidelines for the tr ...... s Diseases Society of America.

@en

type

label

Practice guidelines for the tr ...... s Diseases Society of America.

@ast

Practice guidelines for the tr ...... s Diseases Society of America.

@en

prefLabel

Practice guidelines for the tr ...... s Diseases Society of America.

@ast

Practice guidelines for the tr ...... s Diseases Society of America.

@en

P1433

Q33894467-78995452-744F-4980-8223-F1D37CFED357

P1476

Q33894467-301834A0-DEB8-4588-AC62-239A6C1CE54C

P2093

Q33894467-308603B2-B0B9-404B-9CF3-DBB9360D587C

Q33894467-665A6F4C-18C1-4153-9C35-AD0A678802BA

Q33894467-75E4D81B-7DE5-4168-9F23-8EBD7C56D4CA

Q33894467-7A81DDEC-E30D-4B99-9BBA-CB40CF4815C5

Q33894467-8638DACB-57FF-4AE6-8F37-4BE030246EA4

Q33894467-A0DBDEF1-70A8-48FD-848F-FFB11BF64957

Q33894467-D7B1C511-970C-4CF4-927D-36BE864358AC

P2860

Q33894467-06247887-A661-41F8-8CF7-79AF5CFE9F38

Q33894467-07A44640-9ABF-410B-BDC4-BF7E30D0B3B1

Q33894467-1DDAE6CF-EF72-49F3-94B1-AE3DCF1BD19B

Q33894467-1F641FF4-9AA3-4DF8-BA16-F4BD08F915AE

Q33894467-20DB0821-5309-4141-9064-9D46F231DC54

Q33894467-25A3532C-28C6-4915-AE0E-7198656CE7E9

Q33894467-2A8327B4-EAB5-42A1-BB08-EF95E7662637

Q33894467-2F92AC63-D967-4EF2-B039-560285DA77F3

Q33894467-311141CC-1E63-40E5-84B0-E2DA204B8DCF

Q33894467-326ACDBA-117C-4F17-BD94-568DBDE9B11A

P304

Q33894467-9BC4AEA9-B301-43F9-8069-D92ECBEFBB01

P31

Q33894467-C19ADCA5-16BE-4632-B392-ED290744AD1E

P356

Q33894467-DF05E30A-19D3-4A02-B912-C7AA379362F6

P407

Q33894467-F1BB8A14-C591-4066-B857-DE9B073338A2

P433

Q33894467-AE96849D-2544-4308-8E7D-43B8FAFE318B

P478

Q33894467-029B2DC2-4A6B-4F3E-B3E3-0E8F8DB20CFF

P577

Q33894467-C000C6CB-1E29-49AE-A317-3F128CFF034B

P5875

Q33894467-BFD33EA0-7CC7-41B0-B855-FB480AD48E74

P698

Q33894467-6EB34C02-95C9-4204-A564-85363682332F

P356

P1433

Clinical Infectious Diseases

P1476

Practice guidelines for the tr ...... s Diseases Society of America.

@en

P2093

Dismukes WE

http://www.w3.org/2001/XMLSchema#string

Edwards JE

http://www.w3.org/2001/XMLSchema#string

Filler SG

http://www.w3.org/2001/XMLSchema#string

Pappas PG

http://www.w3.org/2001/XMLSchema#string

Rex JH

http://www.w3.org/2001/XMLSchema#string

Sobel JD

http://www.w3.org/2001/XMLSchema#string

Walsh TJ

http://www.w3.org/2001/XMLSchema#string

P2860

Candida colonization and subsequent infections in critically ill surgical patients

Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.

Candida peritonitis. Report of 22 cases and review of the English literature.

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy.

Treatment options for vulvovaginal candidiasis, 1993.

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

Detection of amphotericin B-resistant Candida isolates in a broth-based system.

Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain.

Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates

P304

662-678

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/313749

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2000-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12545371

http://www.w3.org/2001/XMLSchema#string

P698

10770728

http://www.w3.org/2001/XMLSchema#string